Section 29 (New Zealand) in India
How the section 29 (new zealand) pathway operates in India.
About Section 29 (New Zealand)
New Zealand's Medsafe pathway for unapproved medicines.
How Section 29 (New Zealand) works in India
India's CDSCO permits import of unapproved drugs under Rule 36 for personal use by patients with a prescription from a registered medical practitioner. Named Patient import is common for rare-disease indications.
Patients in India seeking access under Section 29 (New Zealand) typically follow this flow: a licensed physician in India issues the prescription and clinical justification, the regulator reviews and authorises, and an authorised operator coordinates import.
Documents required in India
- Physician prescription and clinical-justification letter.
- Patient identification and consent.
- Country-specific NPP/personal-import form.
- Hospital or clinic attestation where required.
Typical timeline
End-to-end 2-6 weeks in most tier 1 jurisdictions. Cellular and gene therapies may require additional ethics-committee review.